My career has spanned both independent research and scientific leadership, bridging basic science discovery with clinical translation. After initial training in medicinal chemistry and pharmacy (PhD, University of Pittsburgh) and structural biology (post-doc, Yale University and HHMI), I established an independent laboratory at New York University Medical Center, where we studied molecular mechanisms underlying the life- and infection-cycles of cervical cancer-associated papillomaviruses.
Moving to Cincinnati Children's in 2002 provided the exciting opportunity to adapt my research program to benefit from ready access to pediatric clinical programs. My laboratory used a combination of animal models, structure-aided mechanistic biochemistry, transcriptomics, and drug discovery to elucidate mechanisms that promote, and interventions that prevent, the pathological cell proliferation in diseases including cancer, retinopathy and pulmonary arterial hypertension. I also directed the Molecular and Developmental Biology (MDB) PhD program (now renamed the Development, Stem Cells and Regenerative Medicine (DSRM) program, and was the founding director of the Biomedical Research Technologies (BMRT) MS program.
After over three decades of leading an independent, extramurally-funded research laboratory I have transitioned to serving as vice-chair for basic and data sciences at Cincinnati Children's Medical Center overseeing our Discovery Sciences research programs, chief scientific officer for our Innovation Ventures group facilitating the translation of scientific discoveries into practice through commercialization, director of the Office of Research Training and Development Programs focused on upskilling and advancing the careers of our research workforce, and director of our Office of Graduate Studies overseeing graduate programs at Cincinnati Children's. In these roles I continue my deep commitment to research, innovation and translation as well as fostering the training and development of the next generation of scientists.
PhD: University of Pittsburgh, Pittsburgh, PA, 1989.
Post-doctoral Fellowship: Yale University, 1989-1994.
Assistant Professor: New York University School of Medicine, Skirball Institute, 1994-2000.
Associate Professor: Cincinnati Children's Hospital Medical Center, 2001-2007.
Professor: Cincinnati Children's Hospital Medical Center, 2008-present.
Pre-clinical validation of anti-angiogenic agents for use in the treatment of retinopathies, cancer and pulmonary disease.
Molecular mechanisms involved in normal development and in disease states using in vitro (cellular and solution biochemistry and structural biology) and in vivo (mouse models) strategies; developing novel therapeutic strategies via structure-aided drug design coupled with in vitro validation and in vivo pre-clinical studies.
Nanoparticle Delivery of STAT3 Alleviates Pulmonary Hypertension in a Mouse Model of Alveolar Capillary Dysplasia. Circulation. 2021; 144:539-555.
The Eyes Absent proteins in development and in developmental disorders. Biochemical Society Transactions. 2021; 49:1397-1408.
Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis. Molecular Cancer Therapeutics. 2021; 20:803-815.
The Eyes Absent Proteins: Unusual HAD Family Tyrosine Phosphatases. International Journal of Molecular Sciences. 2021; 22:3925.
The multi-functional eyes absent proteins. Critical Reviews in Biochemistry and Molecular Biology (Informa). 2020; 55:372-385.
The Initiation of Meiotic Sex Chromosome Inactivation Sequesters DNA Damage Signaling from Autosomes in Mouse Spermatogenesis. Current Biology. 2020; 30:408-420.e5.
The EYA3 tyrosine phosphatase activity promotes pulmonary vascular remodeling in pulmonary arterial hypertension. Nature Communications. 2019; 10:4143.
An opsin 5-dopamine pathway mediates light-dependent vascular development in the eye. Nature Cell Biology. 2019; 21:420-429.
The Protein Tyrosine Phosphatase Activity of Eyes Absent Contributes to Tumor Angiogenesis and Tumor Growth. Molecular Cancer Therapeutics. 2018; 17:1659-1669.
Modeling tumor cell adaptations to hypoxia in multicellular tumor spheroids. Journal of Experimental and Clinical Cancer Research. 2017; 36:102.
Rashmi S. Hegde, PhD, Paul Spearman, MD ...12/5/2022
Rashmi S. Hegde, PhD11/17/2022